News

Cytogen expects to begin the first US phase I clinical trial of CYT-500 in patients with hormone-refractory prostate cancer subject to institutional review board approval at the planned

The approval for the three abbreviated new drug applications (ANDAs) broadens Accentia’s pain product portfolio, especially for chronic pain indications. Teamm Pharmaceuticals, Accentia’s wholly owned specialty pharmaceutical subsidiary,

Sirtex’ SIR-Spheres microspheres are the only FDA-approved radioactive microspheres for the treatment of metastatic liver tumors. Xeloda (capecitabine), meanwhile, is the only FDA-approved oral chemotherapy for metastatic breast

Based on results from the trial, Mission Pharmacal plans to file a supplemental new drug application (sNDA) with the FDA for the use of Tindamax (tinidazole) as a

Bronchial thermoplasty, a minimally invasive procedure, uses Asthmatx’ Alair system to deliver heat to the airway walls to reduce the presence of airway smooth muscle, the tissue responsible

In its research efforts with S2, GEN ID is seeking to develop yet another class of compounds to counteract the resistance that H5N1 is acquiring through mutations. The

The first step of the cooperation will consist of a feasibility test for the manufacturing of the drug, an infusion-administered alpha 1-proteinase inhibitor (API), from the European company’s

Among the main findings is that 1-tetradecanol complex (1-TDC) significantly inhibited the growth of actinomyces viscosus, a microbe that has been shown to play a major role in

Pirfenidone is the company’s small molecule drug candidate that is being developed for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in its phase III program, named